Efficacy and safety of upadacitinib in Takayasu arteritis (SELECT-TAK): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Rheumatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles